Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus
NCT ID: NCT02276573
Last Updated: 2023-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13 participants
INTERVENTIONAL
2015-03-30
2016-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The literature data moving towards an autoimmune origin, but the pathophysiological mechanisms of OLP remain unknown.
This project represents the first part of a comprehensive project to examine the oral pathogenesis of different viruses (Herpes and papillomavirus HPV) and centered on Epstein-Barr Virus (EBV).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Lichen Planus and Systemical Oncological Comorbidities
NCT06449248
Photobiomodulation, Er:YAG Laser, and Clobetasol in the Treatment of Oral Lichen Planus.
NCT07278999
Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
NCT02443311
Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus
NCT03386643
Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream
NCT00321750
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral lichen planus disease
buccal cavity sample
buccal cavity sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
buccal cavity sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical and/or histological diagnosis of erosive or atrophic OLP
* No signs of severe dysplasia at the sampling
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital saint Roch
Nice, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Raybaud H, Olivieri CV, Lupi-Pegurier L, Pagnotta S, Marsault R, Cardot-Leccia N, Doglio A. Epstein-Barr Virus-Infected Plasma Cells Infiltrate Erosive Oral Lichen Planus. J Dent Res. 2018 Dec;97(13):1494-1500. doi: 10.1177/0022034518788282. Epub 2018 Jul 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-AOI-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.